Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q7Z3C6
UPID:
ATG9A_HUMAN
Alternative names:
APG9-like 1; mATG9
Alternative UPACC:
Q7Z3C6; Q3ZAQ6; Q6P0N7; Q7Z317; Q7Z320; Q8NDK6; Q8WU65; Q9BVL5; Q9H6L1; Q9HAG7
Background:
Autophagy-related protein 9A (APG9-like 1, mATG9) is a pivotal phospholipid scramblase facilitating autophagy through autophagosomal membrane expansion. It dynamically transitions between the preautophagosomal structure and the cytoplasmic vesicle pool, enriching the autophagosome with necessary phospholipids. Its lipid scramblase activity is crucial for distributing phospholipids across the bilayer, driven by ATG2-mediated transfer, thereby promoting membrane growth. Additionally, it aids in recruiting PI4KB to the autophagosome initiation site via ARFIP2, enhancing phosphatidylinositol 4-phosphate availability.
Therapeutic significance:
Understanding the role of Autophagy-related protein 9A could open doors to potential therapeutic strategies.